Akbar Aliasgharzadeh1, Mohammad Khalili2, Elham Mirtaheri3, Bahram Pourghassem Gargari3, Farnaz Tavakoli1, Mahdieh Abbasalizad Farhangi4, Hossein Babaei5, Parvin Dehghan6. 1. Faculty of Medicine, Bone Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Neurosciences Research Center Tabriz University of Medical Sciences, Tabriz, Iran. 3. Department of Biochemistry and Nutrition, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Department of Community Nutrition, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran. 5. Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. 6. Nutrition research center, Department of Food Science and Technology, Student Research committee, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
PURPOSE: This trial was conducted to evaluate the effects of oligofructose-enriched inulin on some of cardiovascular disease risk factors in women with type 2 diabetes. METHODS:52 females (25<BMI<35 kg/m2) with type 2 diabetes were randomly assigned to two groups. Participants received 10g/d oligofructose-enriched inulin (n=27) or 10g/d placebo (n=25) for 8 weeks. Fasting blood samples were taken to measure metabolic profiles, malondialdehyd and antioxidant enzymes at baseline and after the 8 weeks intervention. Paired, unpaired sample t-test and analysis of covariance were used to comparison of quantitative variables. RESULTS: After 8 weeks, in the oligofructose-enriched inulin group there was a significant increase in total antioxidant capacity (0.2 mmol/l, 20.0%) and a significant decrease in fasting plasma glucose (19.2 mg/dL, 9.4%) HbA1c (0.5%, 8.4%), total cholesterol (TC) (28.0 mg/dL, 14.1%), low-density lipoprotein cholesterol (LDL-c) (22.0 mg/dL, 21.7%), TC/HDL-c ratio (0.73, 20.7%), LDL-c/HDL-c ratio (0.55, 27.5%) and malondialdehyd (1.7 nmol/ml, 39.7%) compared to the placebo group. Changes in concentrations of triglycerides, high-density lipoprotein cholesterol (HDLc), superoxide dismutase, catalase and glutathione peroxidase were not significant in oligofructose-enriched inulin group compared to the placebo group. CONCLUSION:Oligofructose-enriched inulin may improve glycemic indices, lipid profile, antioxidant status and malondialdehyd in women with type 2 diabetes.
RCT Entities:
PURPOSE: This trial was conducted to evaluate the effects of oligofructose-enriched inulin on some of cardiovascular disease risk factors in women with type 2 diabetes. METHODS: 52 females (25<BMI<35 kg/m2) with type 2 diabetes were randomly assigned to two groups. Participants received 10g/d oligofructose-enriched inulin (n=27) or 10g/d placebo (n=25) for 8 weeks. Fasting blood samples were taken to measure metabolic profiles, malondialdehyd and antioxidant enzymes at baseline and after the 8 weeks intervention. Paired, unpaired sample t-test and analysis of covariance were used to comparison of quantitative variables. RESULTS: After 8 weeks, in the oligofructose-enriched inulin group there was a significant increase in total antioxidant capacity (0.2 mmol/l, 20.0%) and a significant decrease in fasting plasma glucose (19.2 mg/dL, 9.4%) HbA1c (0.5%, 8.4%), total cholesterol (TC) (28.0 mg/dL, 14.1%), low-density lipoprotein cholesterol (LDL-c) (22.0 mg/dL, 21.7%), TC/HDL-c ratio (0.73, 20.7%), LDL-c/HDL-c ratio (0.55, 27.5%) and malondialdehyd (1.7 nmol/ml, 39.7%) compared to the placebo group. Changes in concentrations of triglycerides, high-density lipoprotein cholesterol (HDLc), superoxide dismutase, catalase and glutathione peroxidase were not significant in oligofructose-enriched inulin group compared to the placebo group. CONCLUSION:Oligofructose-enriched inulin may improve glycemic indices, lipid profile, antioxidant status and malondialdehyd in women with type 2 diabetes.
Entities:
Keywords:
Antioxidants; Lipid profile; MDA; Prebiotic; Type 2 diabetes
Authors: Lisa R Hoving; Margreet R de Vries; Rob C M de Jong; Saeed Katiraei; Amanda Pronk; Paul H A Quax; Vanessa van Harmelen; Ko Willems van Dijk Journal: Nutrients Date: 2018-02-03 Impact factor: 5.717
Authors: Lisa R Hoving; Saeed Katiraei; Amanda Pronk; Marieke Heijink; Kelly K D Vonk; Fatiha Amghar-El Bouazzaoui; Rosalie Vermeulen; Lizette Drinkwaard; Martin Giera; Vanessa van Harmelen; Ko Willems van Dijk Journal: Sci Rep Date: 2018-11-08 Impact factor: 4.379
Authors: Hyeon Yeong Ahn; Minjoo Kim; Cho Rong Seo; Hye Jin Yoo; Sang-Hyun Lee; Jong Ho Lee Journal: Nutr Diabetes Date: 2018-07-19 Impact factor: 5.097